Pliant downgraded at Stifel on bexotegrast trial discontinuation
Source: SeekingAlpha
2025-03-04 10:32:18 ET
More on Pliant Therapeutics
- Pliant Therapeutics: Strange Volatility
- Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF
- Pliant stock jumps 28% on bexotegrast study update
- Seeking Alpha’s Quant Rating on Pliant Therapeutics
- Historical earnings data for Pliant Therapeutics
Read the full article on Seeking Alpha
For further details see:
Pliant downgraded at Stifel on bexotegrast trial discontinuation
Pliant Therapeutics Inc.
NASDAQ: PLRX
PLRX Trading
-1.82% G/L:
$1.345 Last:
366,040 Volume:
$1.41 Open:
PLRX Latest News
March 11, 2026 04:05:00 pm
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
February 23, 2026 08:00:00 am
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
PLRX Stock Data
$72,817,521
56,533,434
3.63%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
